Economic end points in phase II trials.
Mark
D B
DB
Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Durham, NC 27715, USA.
Simons
T A
TA
D002317:Cardiovascular Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D016896:Treatment Outcome
D002317:Cardiovascular Agents